University of Groningen
ColoPulse tablets in inflammatory bowel disease
Maurer, Marina
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Maurer, M. (2017). ColoPulse tablets in inflammatory bowel disease: Formulation, potential application and evaluation. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
ABOUT THE AUTHOR
183
Curriculum vitae
Marina Maurer was born on January 18 1979 in Kampen (Overijssel, the Netherlands). She studied pharmacy at the University of Groningen (1997-2003) and graduated cum laude. She specialised in analytical chemistry and developed an interest in hospital pharmacy. In 2001 and 2002 she worked in short term jobs during summer in the laboratory of the hospital pharmacy of the University Medical Centre Groningen (UMCG).
After graduation Marina started working as a pharmacist in the Scheeperziekenhuis Emmen, the Netherlands. In 2004 she was appointed at the University Medical Centre Groningen, where she worked as a clinical trial pharmacist combined with pharmaceutical patient care.
From 2007 to 2010 she was trained as a hospital pharmacist under supervision of professor Jos Kosterink. As part of this training she specialized in pharmaceutical compounding. The research part of this training, conducted in collaboration with Dr. Reinout Schellekens, formed the starting point of the PhD project on further development and application of the ColoPulse technology. In January 2011 she was registered as a hospital pharmacist and started working at the compounding department of the UMCG, in charge of individual preparations.
Marina spends her spare time playing the violin in several orchestras and a string quartet. She is married with Albertjan Tollenaar and mother of Rosan (2012) and Vygo (2013). Together they love to travel and explore new destinations.
ABOUT THE AUTHOR
184
List of publications
Lefrandt JD, Maurer JM. Oxybutinin for hyperhidrosis. Neth J Med. 2007;65:356
Buijs C, Mom CH, Willemse PH, Boezen M, Maurer JM, Wymenga AN, Jong RS de, Nieboer P, Vries EG de, Mourits MJ. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double blind, randomized cross-over study. Breast Cancer Res Treat. 2009;115:573-580
Panday PV, Vischjager P, Rodgers MG, Maurer JM, Sturkenboom MG, Nijsten MW. Rifampicin treatment of persistently elevated benzodiazepine metabolites in a comatose patient. Intensive Care Med 2009;35:1647-1648
Maurer JM, Dillingh JH, Heiden J van der, Uges DRA, Kosterink JGW, Bos AF, Schellekens RCA. Ontwikkeling van een ready-to-use glucose-calciuminfusievloeistof voor premature neonaten. PW/WP 2009;3:135-140 Maurer JM, Kouwen S, Woerdenbag, Brouwers JRBJ, Kosterink JGW, Schellekens RCA. Farmacotherapeutisch rationaliteit van apotheekbereidingen: evaluatie en toepasbaarheid van de LNA-procedure Farmacotherapeutische plaatsbepaling apotheekbereidingen. PW/WP 2009;3:217-222
Maring JG, Wachters FM, Maurer JM, Uges DRA, Vries EGE de, Groen HJM. Gemcitabine and epirubicin plasma concentration-related excretion in saliva in non-small cell lung cancer patients. Ther Drug Monit 2010;32:364-368
Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen MH, Uges DRA, Vries EGE de, Groen HJM. Pharmacokinetics of gemcitabine in non-small cell lung cancer patients: impact of the 79AC cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66:611-617
Maurer JM*, Schellekens RC*, Wutzke KD, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG, Stellaard F. A non-invasive, low-cost study design to determine the release profile of colon drug delivery sytems: a feasibility study. Pharm Res 2012;29:2070-2078
ABOUT THE AUTHOR
185 Maurer JM, Schellekens RC, van Rieke HM, Stellaard F, Wutzke KD, Buurman DJ, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG. ColoPulse tablets perform comparably in healthy volunteers and Crohn’s patients and show no influence of food and time of food intake on bioavailability. J Control Release 2013; 172: 618-624
Maurer JM, Schellekens RCA, Wutzke KD, Stellaard FS Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations. IEHS 2013;49: 473-491
Buurman DJ* , Maurer JM* , Keizer RJ, Kosterink JGW, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharm Ther 2015;42:529-539
Buurman DJ* , Maurer JM* , Keizer RJ, Kosterink JGW, Dijkstra G. Letter: infliximab therapy for patients with inflammatory bowel disease-some unanswered questions. Authors’reply. Aliment Pharmacol Ther 2015;42:1134 Maurer JM, Schellekens RCA, Rieke HM van, Wanke C, Iordanov V, Stellaard F, Wutzke KD, Dijkstra G, Zee M van der, Woerdenbag HJ, Frijlink HW, Kosterink JGW. Gastrointestinal pH and transit time profiling in healthy volunteers using the IntelliCap system confirms ileo-colonic release of ColoPulse tablets. PlosOne 2015;10:doi 10.1371/journal.pone.0129076
Maurer JM, Hofman S, Schellekens RCA, Tonnis WF, Dubois AOT, Woerdenbag HJ, Hinrichs WLJ, Kosterink JGW, Frijlink HW. Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: a feasibility study. Int J Pharm 2016;505:175-186
